您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (10): 23-37.doi: 10.6040/j.issn.1671-7554.0.2022.0743

• 临床医学 • 上一篇    下一篇

基于SEER数据库构建并验证IIIB期非小细胞肺癌患者预后模型

赵启迪1*,王凯1*,赵小刚2,闫涛1,王亚东1,杜贾军1,3   

  1. 1.山东大学附属山东省立医院肿瘤研究所, 山东 济南 250021;2. 山东大学第二医院胸外科, 山东 济南 250033;3.山东大学附属山东省立医院胸外科, 山东 济南 250021
  • 发布日期:2023-11-08
  • 通讯作者: 杜贾军. E-mail:dujiajun@sdu.edu.cn*共同第一作者.
  • 基金资助:
    国家自然科学基金(82102700);山东省自然科学基金(ZR2019PH002)

Constructing and validating a prognostic model for patients with stage IIIB non-small cell lung cancer based on SEER database

ZHAO Qidi1*, WANG Kai1*, ZHAO Xiaogang2, YAN Tao1, WANG Yadong1, DU Jiajun1,3   

  1. 1. Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China;
    2. Department of Thoracic Surgery, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250033, Shandong, China;
    3. Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China
  • Published:2023-11-08

PDF (PC)

164

摘要： 目的 探讨IIIB期非小细胞肺癌(NSCLC)患者的预后,并构建临床可广泛应用的预后预测工具。 方法 应用监测、流行病学和最终结果(Surveillance, Epidemiology, and End Result, SEER)数据库回顾性收集IIIB期非小细胞肺癌患者临床信息,将患者以7∶3比例随机分为训练集和验证集。另收集2005至2019年就诊于山东大学附属山东省立医院胸外科的IIIB期非小细胞肺癌患者信息作为次要验证集(SPH验证集)。在训练集中进行单因素和多因素Cox比例风险回归分析以构建列线图和网络工具。应用R软件进行ROC曲线、C指数和DCA曲线分析以评估列线图预后模型以及临床获益。 结果 研究共纳入7 903例患者(其中训练集5 532例,验证集2 371例)。预后列线图中最终纳入10个变量,包括性别、年龄、肿瘤原发部位、肿瘤分化程度、肿瘤组织学类型、TNM分期(第八版IIIB期具体亚组)、是否行区域淋巴结清扫、手术范围、是否行放疗和是否行化疗。在训练集和验证集中,5 年AUC值分别为0.724和0.708。训练集、验证集和SPH验证集的C指数分别为0.661、0.649和0.685。校准图显示模型具有良好的预测能力。相较于单纯放化疗,IIIB期患者接受手术联合化疗后预后最佳(P<0.001)。此外,研究可视化预后模型并构建交互式网络工具。 结论 成功构建预后列线图以及交互式网络工具。

关键词: 列线图, 肺鳞状细胞癌, 肺腺癌, 预后, 治疗, 网络工具

Abstract: Objective To investigate the prognosis of patients with stage IIIB non-small cell lung cancer(NSCLC)and to construct a prognostic tool that can be widely used in clinical practice. Methods Clinical data of patients with stage IIIB NSCLC were retrospectively collected from the Surveillance, Epidemiology and End Result(SEER)databases, and randomly grouped into the training set and validation set with a 7∶3 ratio. Information of patients with stage IIIB NSCLC treated in the Department of Thoracic Surgery of Shandong Provincial Hospital Affiliated to Shandong University during 2005 and 2019 was collected as a secondary validation set(SPH validation set). Univariate and multivariate Cox proportional hazards regression analyses were conducted in the training set to construct a nomogram and web tool. Receiver operating characteristic(ROC)curve, concordance index(C-index), and decision curve analyses were performed using R software to evaluate the nomogram and assess the clinical benefits. Results A total of 7,903 patients were involved, including 5,532 in the training set and 2,371 in the validation set. Altogether 10 variables were included in the nomogram, including gender, age, primary site of tumor, grade of tumor, histology of tumor, tumor-node-metastasis stage specific subgroups of ⅢB stage in the eighth edition, dissection of regional lymph node, extent of surgery, radiotherapy and chemotherapy. The area under the ROC curve(AUC)of 5-year overall survival(OS)was 0.724 and 0.708 in the training and validation sets, respectively. The C-index was 0.661, 0.649 and 0.685 in the training, validation and SPH validation sets, respectively. The calibration plot showed that the model had good predictive power. Surgery with chemotherapy was identified as the optimal treatment strategy compared to chemotherapy or radiotherapy alone(P<0.001). An interactive web tool was also constructed. Conclusion A prognostic nomogram was successfully constructed and an interactive web tool to predict patients’ survival was built.

Key words: Nomogram, Lung squamous cell carcinoma, Lung adenocarcinoma, Prognosis, Therapy, Web tool

中图分类号: 

  • R574
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 吴一龙.局部晚期(Ⅲ期)非小细胞肺癌诊断治疗之共识[J]. 当代医学, 2002, 12(8): 37.
[3] Allaeys T, Berzenji L, Lauwers P, et al. Multimodality treatment including surgery related to the type of N2 involvement in locally advanced non-small cell lung cancer [J]. Cancers(Basel), 2022, 14(7): 1656. doi: 10.3390/cancers14071656.
[4] Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming(eighth)edition of the TNM classification for lung cancer [J]. J Thorac Oncol, 2016, 11(1): 39-51.
[5] 黄利生, 伍方财, 林柏翰, 等. 同步推量加速调强放疗联合化疗治疗局部晚期非小细胞肺癌的前瞻性研究[J]. 中国医学物理学杂志, 2022, 39(3): 272-276. HUANG Lisheng, WU Fangcai, LIN Baihan, et al. Simultaneous modulated accelerated radiotherapy combined with chemotherapy for the treatment of locally advanced non-small cell lung cancer: a prospective study [J]. Chinese Journal of Medical Physics, 2022, 39(3): 272-276.
[6] The Lancet Respiratory Medicine. Lung cancer immunotherapy biomarkers: refine not reject [J]. Lancet Respir Med, 2018, 6(6): 403. doi: 10.1016/S2213-2600(18)30180-2.
[7] Smirnova EA, Polotskiǐ BE, Malaev SM, et al. Large cell carcinoma of the lung: ultrastructural classification, diagnosis, prognosis [J]. Arkh Patol, 1994, 56(2): 11-15.
[8] Lindsay CR, Shaw EC, Moore DA, et al. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists [J]. Br J Cancer, 2021, 125(9): 1210-1216.
[9] Wang S, Yang L, Ci B, et al. Development and validation of a nomogram prognostic model for SCLC patients [J]. J Thorac Oncol, 2018, 13(9): 1338-1348.
[10] Evison M, AstraZeneca UKL. The current treatment landscape in the UK for stage III NSCLC [J]. Br J Cancer, 2020, 123(Suppl 1): 3-9.
[11] Zhao L, Wang Z, Du H, et al. Lung adenocarcinoma patient harboring EGFR-KDD achieve durable response to afatinib: a case report and literature review [J]. Front Oncol, 2021, 11: 605853. doi: 10.3389/fonc.2021.605853.
[12] Huber RM, Kauffmann-Guerrero D, Hoffmann H, et al. New developments in locally advanced nonsmall cell lung cancer [J]. Eur Respir Rev, 2021, 30(160): 200227. doi: 10.1183/16000617.0227-2020.
[13] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南2021[M]. 北京: 人民卫生出版社. 2021.
[14] National Comprehensive Cancer Network. NCCN clinical practice guidelines in non-small cell lung cancer(2022.V3)[EB/OL].(2022-06-20)[2023-09-16]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450.
[15] Curran Jr WJ, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410 [J]. J Natl Cancer Inst, 2011, 103(19): 1452-1460.
[16] Wang YQ, Liu XD, Bai WL, et al. Identification of resectable N2 in NSCLC: a single center experience and review of the SEER database [J]. Front Oncol, 2021, 11: 647546. doi: 10.3389/fonc.2021.647546.
[17] Kommalapati A, Tella SH, Appiah AK, et al. Association between treatment facility volume, therapy types, and overall survival in patients with stage IIIA non-small cell lung cancer [J]. J Natl Compr Canc Netw, 2019, 17(3): 229-236.
[18] Yoshino I, Yoshida S, Miyaoka E, et al. Surgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004 [J]. J Thorac Oncol, 2012, 7(5): 850-855.
[19] Park K, Vansteenkiste J, Lee KH, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS [J]. Ann Oncol, 2020, 31(2): 191-201.
[20] Tabchi S, Kassouf E, Rassy EE, et al. Management of stage III non-small cell lung cancer [J]. Semin Oncol, 2017, 44(3): 163-177.
[21] Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer [J]. Curr Treat Options Oncol, 2019, 20(4): 27. doi: 10.1007/s11864-019-0624-7.
[22] Liang W, He J, Shen Y, et al. Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry [J]. J Clin Oncol, 2017, 35(11): 1162-1170.
[23] Young KA, Efiong E, Dove JT, et al. External validation of a survival nomogram for non-small cell lung cancer using the national cancer database [J]. Ann Surg Oncol, 2017, 24(6): 1459-1464.
[24] Wu LL, Chen WT, Liu X, et al. A nomogram to predict long-term survival outcomes of patients who undergo pneumonectomy for non-small cell lung cancer with stage I-IIIB [J]. Front Surg, 2021, 8: 604880. doi: 10.3389/fsurg.2021.604880.
[25] 叶波, 赵珩. 第八版国际肺癌TNM分期修订稿解读[J]. 中国肺癌杂志, 2016, 19(6): 337-342. YE Bo, ZHAO Heng. Revision of the TNM stage grouping in the forthcoming eighth edition of the TNM classification for lung cancer [J]. Chin J Lung Cancer, 2016, 19(6): 337-342.
[26] Ko EC, Raben D, Formenti SC. The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer [J]. Clin Cancer Res, 2018, 24(23): 5792-5806.
[27] Ettinger DS, Wood DE, Aisner DL, et al. NCCN Guidelines insights: non-small cell lung cancer, version 2.2021 [J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[28] Sampath S. Treatment: radiation therapy [J]. Cancer Treat Res, 2016, 170: 105-118. doi: 10.1007/978-3-319-40389-2_5.
[29] Vannucci F, Gonzalez-Rivas D. Is VATS lobectomy standard of care for operable non-small cell lung cancer? [J]. Lung Cancer, 2016, 100: 114-119. doi: 10.1016/j.lungcan.2016.08.004.
[30] Albain K, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J]. The Lancet, 2009, 374(9687): 379-386.
[31] Liao Y, Wang X, Zhong P, et al. A nomogram for the prediction of overall survival in patients with stage II and III non-small cell lung cancer using a population-based study [J]. Oncol Lett, 2019, 18(6): 5905-5916.
[32] Chen X, Pang Z, Wang Y, et al. The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results(SEER)database [J]. Lung Cancer, 2020, 139: 94-102. doi: 10.1016/j.lungcan.2019.11.006.
[1] 巩性军，吴树明，张供，李守先，庞昕焱. 无顶冠状静脉窦综合征的诊断和外科治疗[J]. 山东大学学报(医学版), 2209, 47(6): 129-.
[2] 宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[3] 杜圣红,李晓梅,陈晨,王玲. 鼻型弥漫大B细胞淋巴瘤合并肺腺癌1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(8): 111-115.
[4] 王骏仁,李道卫,王星光,姜淑娟. 吸入布地奈德/福莫特罗治疗新型冠状病毒感染后咳嗽的疗效[J]. 山东大学学报 (医学版), 2023, 61(8): 50-53.
[5] 丁汉东,钟金彪,王琴,廖贵益. ABO血型不相容亲属肾移植12例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(8): 67-73.
[6] 李军秀,袁莹莹,黄凌燕,赵君利. 子宫内膜CD38表达对胚胎移植前抗炎治疗的临床价值[J]. 山东大学学报 (医学版), 2023, 61(8): 54-60.
[7] 孟健丽,王庆港. 生物信息学方法探讨VPS72在肺腺/鳞癌中的表达及潜在作用机制[J]. 山东大学学报 (医学版), 2023, 61(8): 40-49.
[8] 曹广磊,李季,闫飞,林鹏,侯为开,侯新国,陈丽. 甲状腺激素抵抗综合征伴高泌乳素血症1例[J]. 山东大学学报 (医学版), 2023, 61(6): 113-116.
[9] 徐荣坤,王连雷,原所茂,田永昊,刘新宇. 腰椎术中腹主动脉损伤1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(6): 121-124.
[10] 蔡强,单悌超,吴晗. 临终病情评估单预测临终患者生存期的效果[J]. 山东大学学报 (医学版), 2023, 61(5): 79-83.
[11] 刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.
[12] 殷钏杰,陈国玲,康随芳,张琪晨,曹媛,王晓映,张飞雪. 脉络膜黑色素瘤伴视网膜脱离1例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(5): 119-121.
[13] 唐小雨,王云彦,史有奎,王敏. 肉芽肿性多血管炎继发肥厚性硬脑膜炎1例[J]. 山东大学学报 (医学版), 2023, 61(5): 122-124.
[14] 刘士标,张淑君,李培龙,杜鲁涛,王传新. cg20657709位点甲基化对肺腺癌早期诊断的初步探讨[J]. 山东大学学报 (医学版), 2023, 61(4): 18-25.
[15] 胡立勇,钟浩,房娟娟,国巍,张雨露,范医东. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报 (医学版), 2023, 61(4): 49-55.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[2] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[3] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60 -66 .
[4] 龙婷婷,谢明,周璐,朱俊德. Noggin蛋白对小鼠脑缺血再灌注损伤后学习和记忆能力与齿状回结构的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 15 -23 .
[5] 李宁,李娟,谢艳,李培龙,王允山,杜鲁涛,王传新. 长链非编码RNA AL109955.1在80例结直肠癌组织中的表达及对细胞增殖与迁移侵袭的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 38 -46 .
[6] 郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72 -76 .
[7] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7 -14 .
[8] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24 -31 .
[9] 徐玉香,刘煜东,张蓬,段瑞生. 101例脑小血管病患者脑微出血危险因素的回顾性分析[J]. 山东大学学报 (医学版), 2020, 1(7): 67 -71 .
[10] 史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47 -52 .
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发